What is the WHO functional class? The World Health Organization (WHO) functional class describes how severe a patient’s pulmonary hypertension (PH) symptoms are.2 There are four different classes – I is the mildest and IV the most severe form of PH.

2022年8月22日 · 除了常规的临床表现外，WHO功能分级（World Health Organization functional class ，WHO-FC)用于评价PAH患者功能状态，分为Ⅰ~Ⅳ级，其分级原则与纽约心脏病协会心功能分级相似，但增加了晕厥症状的描述。

In summary, this report describes the first comprehensive analysis of the long-term clinical outcomes of PAH patients in FC I or II assessing both observational real-world registries and RCTs. Our meta-analysis of survival stratified by FC establishes that the risk of death for patients with FC I or II PAH is considerable.

用于肺动脉高压患者的临床症状评估。 对于未治疗的特发性肺动脉高压或遗传性肺动脉高压患者，WHO-FC Ⅳ级的患者中位生存期为6个月，WHO-FC Ⅲ级中位生存期为2.5年，WHO-FC Ⅰ或Ⅱ级中位生存期为6年。 Guidelines on diagnosis and treatment of pulmonary arterial hypertension，ESC，2009. 下载梅斯医学APP，方便讨论，随时阅读！ 立即前往下载 >>

There are four functional classes that are used to rate how ill PH patients are. Currently, the World Health Organization or WHO class system is used to describe these patients. It is important to distinguish WHO functional class from WHO group.

2021年8月24日 · The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning, but no equivalent patient-reported version of PAH symptoms and activity limitations exists.

Patients are classified into one of the following four categories: FC I (asymptomatic), FC II (mild), FC III (moderate), and FC IV (severe). In this report, PAH refers to Group 1 (excluding Group 1’ and subgroup 1.5) of the Dana Point 2008 classification for pulmonary hypertension.

Pulmonary arterial hypertension (PAH) is a severe, progressive condition of the small pulmonary vessels that leads to increased pulmonary vascular resistance, right...

2021年8月24日 · The PH-FC-SR provides a structured measure of patient-reported symptoms and activity limitations in PAH for use in a variety of settings, including routine clinical practice, research contexts (such as clinical trials), and patients' self-monitoring of their PAH at home.

2025年3月8日 · Subcutaneous Treprostinil was approved for the treatment of PAH patients with WHO-FC II-IV in 2002 . A 12-week double-blind, placebo-controlled, multicentric trial was performed with 470 patients suffering from Idiopathic PAH and PAH associated with connective tissue disease and congenital heart disease between November 1998 and October 1999 ...